JP2025512950A5 - - Google Patents
Info
- Publication number
- JP2025512950A5 JP2025512950A5 JP2024559130A JP2024559130A JP2025512950A5 JP 2025512950 A5 JP2025512950 A5 JP 2025512950A5 JP 2024559130 A JP2024559130 A JP 2024559130A JP 2024559130 A JP2024559130 A JP 2024559130A JP 2025512950 A5 JP2025512950 A5 JP 2025512950A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263328951P | 2022-04-08 | 2022-04-08 | |
| US63/328,951 | 2022-04-08 | ||
| PCT/US2023/065489 WO2023196943A1 (en) | 2022-04-08 | 2023-04-07 | Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025512950A JP2025512950A (ja) | 2025-04-22 |
| JP2025512950A5 true JP2025512950A5 (https=) | 2026-04-14 |
Family
ID=86272460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559130A Pending JP2025512950A (ja) | 2022-04-08 | 2023-04-07 | Ｄｒ５アゴニストとｐｌｋ１阻害剤又はｃｄｋ阻害剤との併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250215101A1 (https=) |
| EP (1) | EP4504785A1 (https=) |
| JP (1) | JP2025512950A (https=) |
| KR (1) | KR20250004725A (https=) |
| CN (1) | CN119365489A (https=) |
| AU (1) | AU2023248848A1 (https=) |
| CA (1) | CA3247628A1 (https=) |
| IL (1) | IL316085A (https=) |
| MX (1) | MX2024012300A (https=) |
| TW (1) | TW202404636A (https=) |
| WO (1) | WO2023196943A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024097179A1 (en) * | 2022-11-02 | 2024-05-10 | Vincerx Pharma, Inc. | Combination therapies comprising a cdk9 inhibitor for cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| WO2003072062A2 (en) | 2002-02-28 | 2003-09-04 | Temple University-Of The Commonwealth System Of Higher Education | Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| JP3876265B2 (ja) | 2003-02-26 | 2007-01-31 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ジヒドロプテリジノン、その製造方法及び薬物形態での使用 |
| CA2541651C (en) | 2003-10-22 | 2011-05-24 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| US7796945B2 (en) | 2006-09-29 | 2010-09-14 | Motorola, Inc. | Method and system for associating devices in a personal area network |
| PL2205603T3 (pl) | 2007-09-28 | 2014-07-31 | Cyclacel Ltd | Pochodne pirymidyny jako inhibitory kinaz białkowych |
| AR076784A1 (es) | 2009-05-26 | 2011-07-06 | Nerviano Medical Sciences Srl | Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico |
| CA2991634C (en) * | 2015-07-16 | 2026-03-17 | Inhibrx Biosciences, Inc. | Multivalent and multispecific dr5-binding fusion proteins |
| IL305265A (en) * | 2021-02-19 | 2023-10-01 | Inhibrx Inc | Preparations of DR5-binding polypeptides |
-
2023
- 2023-04-07 AU AU2023248848A patent/AU2023248848A1/en active Pending
- 2023-04-07 WO PCT/US2023/065489 patent/WO2023196943A1/en not_active Ceased
- 2023-04-07 US US18/853,278 patent/US20250215101A1/en active Pending
- 2023-04-07 CN CN202380042671.1A patent/CN119365489A/zh active Pending
- 2023-04-07 TW TW112113053A patent/TW202404636A/zh unknown
- 2023-04-07 KR KR1020247037073A patent/KR20250004725A/ko active Pending
- 2023-04-07 EP EP23720526.5A patent/EP4504785A1/en active Pending
- 2023-04-07 CA CA3247628A patent/CA3247628A1/en active Pending
- 2023-04-07 JP JP2024559130A patent/JP2025512950A/ja active Pending
- 2023-04-07 IL IL316085A patent/IL316085A/en unknown
-
2024
- 2024-10-03 MX MX2024012300A patent/MX2024012300A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101370497B (zh) | 包含parp抑制剂和细胞毒性剂的联合产品及用途 | |
| Roth et al. | Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120) | |
| Ruch et al. | Hedgehog signaling pathway and cancer therapeutics: progress to date | |
| CN103402519B (zh) | 肿瘤治疗剂 | |
| TW202327569A (zh) | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 | |
| JP2019506403A5 (https=) | ||
| CN109937041B (zh) | 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| CN111527103A (zh) | 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法 | |
| CN120285177A (zh) | Hdac抑制剂和pd-1抑制剂的组合疗法 | |
| JP2014533284A5 (https=) | ||
| JP2021513536A5 (https=) | ||
| JP2019520426A5 (https=) | ||
| JP2019048822A (ja) | Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用 | |
| JP2012507499A5 (https=) | ||
| JP2018519324A5 (https=) | ||
| JP2019525948A5 (https=) | ||
| RU2018146812A (ru) | Фармацевтические комбинации | |
| JP2015524414A5 (https=) | ||
| JP2015519347A5 (https=) | ||
| JP2014512355A5 (https=) | ||
| JP2025512950A5 (https=) | ||
| JP2023524789A5 (https=) | ||
| JP2024515809A5 (https=) | ||
| CN101222850A (zh) | 治疗对药物有抗性的癌症的方法 | |
| TW202102216A (zh) | 抗腫瘤組合物 |